Document is current
Any future updates will be listed below
-
Authors
Bandopadhayay, Pratiti
Ramkissoon, Lori A
Jain, Payal
Bergthold, Guillaume
Wala, Jeremiah
Zeid, Rhamy
Schumacher, Steven E
Urbanski, Laura
O'Rourke, Ryan
Gibson, William J
Pelton, Kristine
Ramkissoon, Shakti H
Han, Harry J
Zhu, Yuankun
Choudhari, Namrata
Silva, Amanda
Boucher, Katie
Henn, Rosemary E
Kang, Yun Jee
Knoff, David https://orcid.org/0000-0001-6233-2893
Paolella, Brenton R
Gladden-Young, Adrianne
Varlet, Pascale
Pages, Melanie
Horowitz, Peleg M
Federation, Alexander
Malkin, Hayley
Tracy, Adam A
Seepo, Sara
Ducar, Matthew
Van Hummelen, Paul
Santi, Mariarita
Buccoliero, Anna Maria
Scagnet, Mirko
Bowers, Daniel C
Giannini, Caterina
Puget, Stephanie
Hawkins, Cynthia
Tabori, Uri
Klekner, Almos
Bognar, Laszlo
Burger, Peter C
Eberhart, Charles
Rodriguez, Fausto J
Hill, D Ashley
Mueller, Sabine
Haas-Kogan, Daphne A
Phillips, Joanna J
Santagata, Sandro
Stiles, Charles D
Bradner, James E
Jabado, Nada
Goren, Alon
Grill, Jacques
Ligon, Azra H
Goumnerova, Liliana
Waanders, Angela J
Storm, Phillip B
Kieran, Mark W
Ligon, Keith L
Beroukhim, Rameen
Resnick, Adam C
- License Information
-
More Information
Article History
Received: 21 August 2015
Accepted: 6 January 2016
First Online: 1 February 2016
Competing interests
: The Dana-Farber Cancer Institute has licensed drug-like derivatives of JQ1 prepared in the Bradner laboratory to Tensha Therapeutics for clinical translation as cancer therapeutics. The Dana-Farber Cancer Institute and J.E.B. have been provided minor equity shares in Tensha Therapeutics.
